These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39424725)

  • 1. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM
    Methods Mol Biol; 2025; 2865():189-219. PubMed ID: 39424725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
    Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
    Della Starza I; Cavalli M; De Novi LA; Genuardi E; Mantoan B; Drandi D; Barbero D; Ciabatti E; Grassi S; Gazzola A; Mannu C; Agostinelli C; Piccaluga PP; Bomben R; Degan M; Gattei V; Guarini A; Foà R; Galimberti S; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2019 Oct; 37(4):368-374. PubMed ID: 31325190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR.
    van der Velden VH; van Dongen JJ
    Methods Mol Biol; 2009; 538():115-50. PubMed ID: 19277574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas.
    Pott C; Tiemann M; Linke B; Ott MM; von Hofen M; Bolz I; Hiddemann W; Parwaresch R; Kneba M
    Leukemia; 1998 Oct; 12(10):1630-7. PubMed ID: 9766510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
    Della Starza I; De Novi LA; Cavalli M; Novelli N; Soscia R; Genuardi E; Mantoan B; Drandi D; Ferrante M; Monitillo L; Barbero D; Ciabatti E; Grassi S; Bomben R; Degan M; Gattei V; Galimberti S; Di Rocco A; Martelli M; Cortelazzo S; Guarini A; Foà R; Ladetto M; Ferrero S; Del Giudice I;
    Hematol Oncol; 2020 Dec; 38(5):698-704. PubMed ID: 32816326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined molecular diagnosis of B-cell lymphomas with t(11;14)(q13;q32) or t(14;18)(q32;q21) using multiplex- and long distance inverse-polymerase chain reaction.
    Vieira L; Martinho A; Antunes O; Silva E; Ambrósio AP; Geraldes MC; Nascimento R; Silva C; Pereira JM; Júnior EC; Jordan P
    Diagn Mol Pathol; 2008 Jun; 17(2):73-81. PubMed ID: 18382373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
    Drandi D; Ferrero S; Ladetto M
    Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.
    Sørensen CD; Jørgensen JM; Nederby L; Hokland P; Nyvold CG
    J Immunol Methods; 2014 Apr; 406():131-6. PubMed ID: 24631717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
    Cavalli M; De Novi LA; Della Starza I; Cappelli LV; Nunes V; Pulsoni A; Del Giudice I; Guarini A; Foà R
    Br J Haematol; 2017 May; 177(4):588-596. PubMed ID: 28419517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
    Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
    Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytometric detection of DNA amplified with fluorescent primers: applications to analysis of clonal bcl-2 and IgH gene rearrangements in malignant lymphomas.
    Barker RL; Worth CA; Peiper SC
    Blood; 1994 Feb; 83(4):1079-85. PubMed ID: 8111048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
    Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
    Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis.
    Beishuizen A; Verhoeven MA; van Wering ER; Hählen K; Hooijkaas H; van Dongen JJ
    Blood; 1994 Apr; 83(8):2238-47. PubMed ID: 8161789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas.
    Genuardi E; Alessandria B; Civita AM; Ferrero S
    Methods Mol Biol; 2022; 2453():119-132. PubMed ID: 35622324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
    Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation diagnostic usefulness of immunoglobulin light chains (Igκ, Igλ) and incomplete IGH D-J clonal gene rearrangements in patients with B-cell non-Hodgkin lymphomas using BIOMED-2 protocol.
    Ghorbian S; Jahanzad I; Javadi GR; Sakhinia E
    Clin Transl Oncol; 2014 Nov; 16(11):1006-11. PubMed ID: 24862097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results].
    Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J
    Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.